Архив отчётов
Вся аналитика
Страница 5 из 45 · 1080 отчётов
47/100
Yuanjie Semiconductor: Real AI-Optics Growth, Zero Margin of Safety
Yuanjie is an upstream IDM laser-chip maker whose product mix flipped from telecom toward AI-driven data-center silicon-photonics CW light sources, lifting 2025 revenue to CNY 601.4 million (gross margin to 58.15%) and driving 2026 H1 guidance up 339-364% year on year. But the same filings show its largest customer alone supplied 53.35% of 2025 sales (up from 16.38% in 2024), the CNY 1.251 billion phase-two expansion withholds its capacity target, and part of the H1 2026 profit surge is non-recurring fair-value gains. Rating Avoid: at CNY 1,445 the stock already prices in years of flawless scaling above even this report's own optimistic CNY 1,180/share fair-value estimate, with a margin-of-safety verdict of none.
36/100
Plug Power: A Real Turnaround With Zero Margin of Safety
Plug Power is a vertically integrated hydrogen platform selling fuel-cell systems, electrolyzers and hydrogen supply, still trying to prove that owning the whole stack creates value rather than just multiplying capital needs. FY2025 revenue reached about $710 million and gross margin turned positive for the first time in Q4 2025, but slid back to negative 13.2% in Q1 2026 while unrestricted cash fell from $368.5 million to a preliminary $162 million by June 30, keeping dilution risk from the ATM and Yorkville programs very much alive, and the DOE's $1.66 billion loan remains suspended rather than functioning as a funding backstop. Rating Watch: real operating progress, but at $2.19 the stock already sits above the report's own $1.25 conservative fair-value estimate with zero margin of safety.
34/100
Generate Biomedicines: The Asset Is Real, the AI Premium Is Still on Trial
Generate Biomedicines is a clinical-stage generative-biology company designing AI-generated protein therapeutics, funding its lead Phase 3 severe-asthma asset GB-0895 from Novartis and Amgen collaboration revenue and a post-IPO cash balance of $516.6 million as of March 2026. The core tension: Q1 2026 collaboration revenue fell to $7.2 million from $8.8 million a year earlier while net loss widened to $61.7 million and operating cash burn reached $80.4 million, so nearly all of the company's value now rests on one late-stage asset that will not complete enrollment until the first half of 2028, even as the stock still trades about 13% below its February 2026 IPO price. Rating Hold: the platform science and cash runway are real, but at $13.90 the market has already priced in a meaningful share of GB-0895's eventual success, leaving little margin of safety for new capital.
36/100
CGN Power: A Real Nuclear Moat, but No Margin of Safety Yet
CGN Power is China's listed nuclear-generation platform under China General Nuclear Power Group, operating 28 reactors with 31.838 GW of capacity at year-end 2025 and one of the industry's largest build-out pipelines, 18 units still under construction as of mid-2026. The core tension: 2025 revenue fell 4.1% to RMB 75.70 billion and Q1 2026 revenue dropped a further 13.25% as refuelling outages hit availability even as market-based tariffs fell about 8.8%, though half-year 2026 data show the decline sharply narrowing as Q2 generation recovered year on year. Rating Hold: a genuine state-backed nuclear moat with a real multi-year build-out runway, but at CNY 4.11 (about 22.5x trailing earnings) the A-shares already price in much of that story with no large margin of safety.
49/100
63Buffett
Rheinmetall: Respect Without Urgency for a Re-Rated Defence Prime
Rheinmetall is Germany's dominant defence prime, an ammunition-and-land-systems specialist riding a record €73.0bn backlog as European rearmament accelerates past €380bn in 2025 defence spending. FY2025 continuing sales rose to €9.94bn at an 18.5% margin, led by a 29.3% margin in the core Weapon and Ammunition unit, but June's abrupt cancellation of the F126 frigate programme wiped out nearly a fifth of the share price in a single day, exposing how much of the celebrated backlog is framework rather than firm order intake. Rating Hold: a genuinely stronger, cleaner defence business than it was two years ago, but a stock still priced at roughly 40x earnings for execution that has not yet been proven immune to political reversal.
48/100
48Buffett
Ningbo Tuopu: Fair for the Auto Business, Pricey for the Robot Option
Ningbo Tuopu is a diversified Chinese Tier 0.5/Tier 1 auto-parts supplier spanning chassis, interior, NVH, thermal management and an early-stage robot-actuator business, with 2025 revenue of CNY 29.58 billion under a founder-controlled ownership structure. The core tension: revenue grew 11.2% in 2025 and 14.9% again in Q1 2026, but attributable profit growth has stalled even as the stock trades near 30x trailing earnings on hopes for a humanoid-robotics ramp that primary filings do not yet support — robot-actuator revenue was only CNY 13.6 million in 2025, under one-twentieth of one percent of group sales. Rating Hold: the auto platform earns a fair multiple on its own, but fresh capital is still paying for a robotics option that has not shown up in the numbers.
47/100
Sichuan Baili Tianheng: A De-Risked ADC Story the Market Has Already Priced In
Sichuan Baili Tianheng (STAR Market 688506, English IR name Sichuan Biokin) is a China-listed oncology biotech whose legacy generics business in anesthesia, parenteral nutrition and traditional Chinese medicine still funds operations, but whose roughly CNY 141 billion market value is now dominated by iza-bren (BL-B01D1), a first-in-class bispecific EGFR×HER3 ADC licensed to Bristol Myers Squibb for $800 million upfront plus billions more in potential milestones. The core tension: 2024 revenue and profit spiked on that upfront payment (revenue up 936% to CNY 5.82 billion), then reverted to a CNY 1.05 billion net loss in 2025 as licensing income normalized, and Q1 2026 still burned CNY 741.8 million of operating cash against just CNY 94.6 million of revenue, all while iza-bren was winning FDA Breakthrough Therapy Designation and its first two China approvals in 2026. Rating Hold: a genuinely de-risked, first-in-class ADC franchise, but at CNY 329.69 the shares already sit near the middle of a reasonable fair-value band with no obvious margin of safety.
36/100
54Buffett
Sanmina Corporation
Sanmina Corporation is a diversified U.S. electronics manufacturing services (EMS) provider whose legacy industrial, medical, and communications manufacturing base was reset upward by the October 2025 acquisition of AMD's ZT Systems data-center manufacturing business. Fiscal Q2 2026 revenue jumped to 4.01 billion USD from 1.98 billion USD a year earlier on accelerated AI-server shipments, but management said some second-half volume pulled forward, and Q3 guidance of 3.2 to 3.5 billion USD sits well below that peak. Rating Hold: the balance sheet now carries 2.17 billion USD of acquisition-related debt, customer concentration remains high (two customers each above 10% of sales), and the current 219.41 USD price already discounts much of the AI-driven re-rating before its durability is proved.
45/100
Tianshui Huatian: A Transition Story the Market Is Already Paying For
Tianshui Huatian is a leading mainland Chinese OSAT (outsourced semiconductor assembly and test) company, packaging and testing chips for automotive, memory, RF and consumer customers from a manufacturing network spanning Tianshui, Xi'an, Kunshan, Nanjing, and Unisem in Malaysia. The core tension: 2025 revenue rose 19.0% to CNY 17.21 billion and net profit grew 15.3% to CNY 711 million, but recurring profit was only CNY 200.4 million once subsidies and fair-value gains are stripped out, while 2025 capex of CNY 6.15 billion far outran operating cash flow — even as the stock traded near 86x trailing earnings after repeated limit-up moves tied to an advanced-packaging and AI narrative. Rating Hold: the packaging upgrade is real, but owner earnings haven't caught up to a price that already assumes it succeeds.
44/100
39Buffett
Telefonaktiebolaget LM Ericsson
Telefonaktiebolaget LM Ericsson is a Swedish telecom-equipment vendor whose revenue still leans on mobile radio-access-network hardware, layered with a high-margin patent-licensing stream and an emerging AI-in-RAN software push. 2025 sales reached SEK 236.7 billion with gross margin recovering to 47.6%, but the July 2026 sell-off, down about 18% in five trading days after a working-capital scare, shows the stock still trades like a cyclical hardware name. Rating Hold: the balance sheet is strong and the repair story is real, but AI-in-RAN monetization remains early and the current SEK 92.80 price does not yet offer enough margin of safety.
40/100
60Buffett
Flex Ltd: The CPI Spin-Off Is Real, But the Stock Has Already Front-Run the Rerating
Flex Ltd is a Singapore-domiciled contract manufacturer now split into two identities under one ticker: a diversified electronics manufacturer serving healthcare, industrial, and communications customers, and a fast-growing Cloud and Power Infrastructure (CPI) arm supplying power, cooling, and cloud hardware for AI data centers, slated for a tax-free spin-off targeted for the first quarter of calendar 2027. Fiscal 2026 revenue reached 27.9 billion USD, with CPI alone growing 38% to 6.6 billion USD at a 9.2% adjusted operating margin, well above the 5.4%-6.0% margins of the legacy segments, while the stock already trades around 55x trailing GAAP earnings and 29x the midpoint of fiscal 2027 adjusted EPS guidance. Rating Hold: the spin-off thesis is real, but today's price already capitalizes much of the post-separation rerating before the final capital structure and standalone disclosures are public.
44/100
38Buffett
MasTec, Inc.
MasTec is a U.S. specialty infrastructure contractor spanning telecom fiber, utility power delivery, gas pipelines, and heavy civil work, now pushing further into data-center electrical systems through its 2026 Superior acquisition. Record 2025 revenue of 14.3 billion USD and an all-time-high 19.0 billion USD backlog justify the recent re-rating, but at 351.40 USD the market is already pricing smooth Superior integration and sustained premium margins. Rating Hold: a genuine transition story, but one priced for a best case rather than a margin of safety.
49/100
75Buffett
NICE Ltd: A Good Software Business Still Waiting for Proof That AI Adds More Than It Substitutes
NICE Ltd is a dual-engine, Nasdaq-listed enterprise software company: a cloud customer-engagement platform for contact centers and AI agents, paired with a financial-crime and compliance franchise built around Actimize. 2025 revenue reached $2.945 billion with 90% recurring revenue and a debt-free balance sheet, yet Q1 2026 non-GAAP cloud gross margin fell to 62.1% from 68.8% a year earlier, and management's Q2 guide of $761-771 million came in below the roughly $777 million consensus even as AI and self-service ARR grew 66% to $345 million. Rating Watch: the stock trades near a decade-low P/E of 9.5x with a genuinely strong balance sheet, but it is not yet clear whether AI is expanding NICE's revenue pool or substituting for the seats and minutes it once sold directly.
42/100
JCET: Advanced-Packaging Ambitions Are Real, But Owner Earnings Haven't Caught Up to the Price
JCET (Jiangsu Changjiang Electronics Technology) is mainland China's largest chip-assembly, advanced-packaging and test provider (OSAT), running production bases in China, Singapore and South Korea for global computing, automotive, storage and industrial customers. The core tension: 2025 revenue rose 8.1% to CNY 38.87 billion but net profit fell 2.8% to CNY 1.57 billion and operating cash flow dropped 20.3%, while the stock still traded near 101x trailing earnings and 5.5x book after a violent stretch in which a CNY 7.8 billion Lingang advanced-packaging plant announcement was followed by a 9.97% one-day drop on a strong H1 2026 profit pre-announcement. Rating Watch: a genuine advanced-packaging franchise with visibly improving mix, but a share price that has run further than owner earnings and capex-adjusted cash flow currently support.
38/100
57Buffett
Zijin Mining: A Real Multi-Metal Compounder, Priced for the Transition to Go Right
Zijin Mining is a dual-listed (Shanghai + Hong Kong) Chinese mining major that has grown from a domestic gold champion into a global gold-copper-lithium portfolio spanning 18 countries, with a roughly 5.5 billion CAD acquisition of Allied Gold's African assets still unclosed as of 2026-07-22. In 2025 revenue rose to CNY 349.1 billion and operating cash flow to CNY 75.4 billion, and first-quarter 2026 net profit jumped 98% to CNY 20.1 billion as mining-enterprise gross margin reached 71.01% and lithium carbonate output surged more than tenfold to 16.2 thousand tonnes. Rating Hold: cash generation and portfolio breadth are genuinely strong, but at CNY 30.21 the A-share already sits inside the fair-value range, leaving limited margin of safety until Allied closes and Kamoa's copper output normalizes.
45/100
64Buffett
Luxshare Precision: A Good Company, but Only a Fair Price
Luxshare Precision is a Shenzhen-listed, Apple-anchored precision manufacturer that has climbed from connectors into a full-stack platform spanning consumer electronics, communications and data-center hardware, and, since absorbing Germany's Leoni, global automotive wiring. In 2025 the newer engines outgrew the legacy base: automotive electronics revenue surged 185.34% to CNY 39.26 billion and communications and data-center revenue rose 33.81% to CNY 24.57 billion at 18.40% gross margin, even as CNY 17.90 billion of capex consumed nearly all of the year's CNY 17.33 billion operating cash flow and one unnamed customer still supplied 56.68% of sales. Rating Hold: a genuinely higher-quality transition story, but one already priced around 24x forward earnings and roughly 44x owner earnings, leaving little margin of safety for a fresh buyer.
45/100
Daiichi Sankyo: A World-Class ADC Franchise, Priced as If the Supply Crisis Is Already Resolved
Daiichi Sankyo is a Japan-based, oncology-focused pharmaceutical company whose profit engine has shifted to the DXd antibody-drug-conjugate platform, led by Enhertu (partnered with AstraZeneca) and Datroway, with the Oncology unit generating JPY 608.8 billion of FY2025 revenue, up 31.3% year on year. In May 2026 the company booked JPY 214.4 billion of manufacturing-related provisions after admitting its ADC supply contracts were sized for maximum-demand scenarios, yet still posted record FY2025 revenue of JPY 2,123.0 billion and guided FY2026 core operating profit up 27.5%, even as it acknowledged that some medium- to long-term supply-cost gaps remain unrecognized. Rating Hold: world-class ADC science, but a stock that has already re-priced into the acceptable-hold zone rather than a clear bargain, with the next proof point resting on two to three clean quarters without another supply-related charge.
48/100
SpaceX: A Strategically Brilliant Platform Wrapped in a Still-Expensive Stock
SpaceX is a newly public, vertically integrated space and AI conglomerate built on three very different businesses: a mature $11.4 billion Starlink broadband franchise that funds the group, a still-loss-making Space/Starship launch arm, and an AI segment (merged with xAI in February 2026) that lost $6.36 billion in 2025 alone. Since its record $75 billion IPO priced the company near $1.77 trillion, the stock has fallen roughly 45% to $124.11, yet still trades near 87x sales while Elon Musk retains 85.1% of voting power under an unusually investor-unfriendly governance structure. Rating Avoid: a genuinely rare platform, but a public price that still assumes flawless execution across Starship, AI, and an August lock-up event with no real margin of safety.
40/100
Nidec Corporation: A Real Motor Franchise Wrapped in a Credibility Discount
Nidec is Kyoto's diversified motor giant, spanning small precision motors, automotive motion systems, and industrial motors across 300-plus group companies built through 75-plus acquisitions. A founder-rooted accounting scandal has triggered a TSE special-alert designation, a suspended dividend, and a pending review of roughly JPY 250 billion in goodwill, even as FY2025 operating profit held at JPY 237.8 billion on JPY 2.608 trillion in sales. Rating Watch: a real industrial franchise wrapped in a credibility discount, not yet cheap enough or de-risked enough to buy.
36/100
BioNTech SE: Cash-Rich Transition, Unproven Oncology Payoff
BioNTech is a German biotech converting one extraordinary COVID-vaccine windfall into a late-stage oncology franchise, backed by €16.8 billion of cash as of Q1 2026. Revenue is collapsing toward a seasonal COVID trough while R&D spending stays heavy, and pumitamig plus gotistobart carry most of the market's oncology hopes. Rating Hold: the balance sheet rules out a bearish call, but unresolved oncology execution and founder-succession risk keep the price fair rather than cheap.
52/100
95Buffett
Mindray Bio-Medical: The Transition Is Real, But So Is the Price Tag
Shenzhen Mindray is China's largest medical-device platform, spanning patient monitoring, in-vitro diagnostics and imaging, with overseas sales above 53% of revenue and recurring business nearing 40% as the APT Medical deal pushes into consumables and intervention. FY2025 revenue fell 9.4% to RMB 33.28 billion and attributable profit dropped to RMB 8.14 billion as domestic hospital budgets tightened, even as international growth stayed healthy and operating cash flow held at RMB 10.14 billion. Rating Hold: a genuine quality compounder mid-transition, but at CNY 150.31 the price already sits inside the acceptable-hold band, leaving little margin of safety until domestic demand stabilizes.
42/100
TDK Corporation: A Real Transition, Priced With Little Room to Wobble
TDK Corporation is a Japanese materials-and-components maker whose four segments -- Passive Components, Sensors, Magnetic Applications, and Energy (batteries, largely the consolidated ATL battery business) -- sell into AI data centers, automotive, and consumer electronics. FY2026 revenue reached a record ¥2.50 trillion with operating profit of ¥272.4 billion on strong nearline-HDD and sensor demand, but Energy still generated more than half of group revenue and the large majority of segment profit, and management guides Energy down for FY2027. Rating Hold: the AI-diversification story is real, but the price already assumes it succeeds, leaving little margin of safety if execution slips.
46/100
57Buffett
SS&C Technologies: A Sticky Cash Engine, Not Yet Cheap Enough
SS&C Technologies is a financial-software-and-outsourced-operations platform embedded in the back-office workflows of asset managers, fund administrators, and healthcare payers, built through roughly 70 acquisitions since 1986 rather than organic product development alone. FY2025 revenue reached $6.27 billion with $1.74 billion of operating cash flow, and organic growth improved to 5.0% in Q1 2026, but goodwill and intangibles still make up about 68% of total assets, AI investments remain economically undisclosed, and one-segment reporting leaves investors dependent on voluntary disclosure. Rating Hold: a genuinely sticky, cash-generative platform whose current price near the conservative-scenario fair value already reflects most of its quality, leaving only a modest margin of safety.
44/100
AbCellera Biologics: A Well-Funded Platform Waiting on One Clinical Proof Point
AbCellera Biologics is a clinical-stage antibody company transitioning from a partner-fee-and-royalty platform to owning its own drug pipeline, anchored by lead candidate ABCL635 heading into Phase 2 data. FY2025 revenue reached $75.1 million but the company still lost $146.4 million, leaving about $655 million of liquidity to fund the transition. Rating Watch: a well-capitalized platform that still needs ABCL635's Q3 2026 efficacy readout before the transition story can be trusted.